Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells by Jin, Quanri et al.
RESEARCH ARTICLE Open Access
Fatty acid synthase phosphorylation: a novel
therapeutic target in HER2-overexpressing breast
cancer cells
Quanri Jin
1†, Linda X Yuan
1†, Delphine Boulbes
1, Jong Min Baek
1, Ying Nai Wang
2, Daniel Gomez-Cabello
1,6,
David H Hawke
3, Sai Ching Yeung
4, Mong Hong Lee
2,5, Gabriel N Hortobagyi
1, Mien Chie Hung
2,5,
Francisco J Esteva
1,2,5*
Abstract
Introduction: The human epidermal growth factor receptor 2 (HER2) is a validated therapeutic target in breast
cancer. Heterodimerization of HER2 with other HER family members results in enhanced tyrosine phosphorylation
and activation of signal transduction pathways. HER2 overexpression increases the translation of fatty acid synthase
(FASN), and FASN overexpression markedly increases HER2 signaling, which results in enhanced cell growth.
However, the molecular mechanism and regulation of HER2 and FASN interaction are not well defined. Lapatinib is
a small-molecule tyrosine kinase inhibitor that blocks phosphorylation of the epidermal growth factor receptor and
HER2 in breast cancer cells, resulting in apoptosis. We hypothesized that FASN is directly phosphorylated by HER2,
resulting in enhanced signaling and tumor progression in breast cancer cells.
Methods: Using mass spectrometry, we identified FASN as one of the proteins that is dephosphorylated by
lapatinib in SKBR3 breast cancer cells. Immunofluorescence, immunoprecipitation, Western blotting, a kinase assay,
a FASN enzymatic activity assay, an invasion assay, a cell viability assay and zymography were used to determine
the role of FASN phosphorylation in invasion of SKBR3 and BT474 cells. The FASN inhibitor C75 and small
interfering RNA were used to downregulate FASN expression and/or activity.
Results: Our data demonstrated that FASN is phosphorylated when it is in complex with HER2. FASN
phosphorylation was induced by heregulin in HER2-overexpressing SKBR3 and BT474 breast cancer cells. Heregulin-
induced FASN phosphorylation resulted in increased FASN enzymatic activity, which was inhibited by lapatinib. The
FASN inhibitor C75 suppressed FASN activity by directly inhibiting HER2 and FASN phosphorylation. Blocking FASN
phosphorylation and activity by lapatinib or C75 suppressed the activity of matrix metallopeptidase 9 and inhibited
invasion of SKBR3 and BT474 cells.
Conclusions: FASN phosphorylation by HER2 plays an important role in breast cancer progression and may be a
novel therapeutic target in HER2-overexpressing breast cancer cells.
Introduction
The human epidermal growth factor receptor 2 (HER2)
gene encodes a 185-kDa transmembrane protein that
belongs to the type I family of growth factor receptors,
which also includes the epidermal growth factor recep-
tor (EGFR), HER3 and HER4. HER2 is overexpressed in
20 to 25% of invasive breast cancers, and patients with
those cancers have worse overall survival and time to
relapse than patients whose tumors express normal
levels of HER2 [1]. This strong link between HER2
activity and the malignant process has made this protein
an excellent target for studies focusing on the develop-
ment of new cancer therapies [2]. The monoclonal anti-
body trastuzumab and the small-molecule tyrosine
kinase inhibitor lapatinib are the first two HER2-
targeted therapies approved by the U.S. Food and Drug
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overexpressing breast cancer [3-5].
HER3 and HER4 bind to the well-characterized ligand
heregulin (HRG), but no ligand has been identified for
the extracellular domain of HER2. One of the mechan-
isms of HER2 activation is its heterodimerization with
other HER family members. For example, upon ligand
binding (that is, with HRG), HER3 can form heterodi-
mers with HER2, resulting in markedly enhanced tyro-
sine phosphorylation of HER2 [6] and subsequent
transphosphorylation of HER3 [7]. Like EGFR, HER2
has intrinsic tyrosine kinase activity and can interact
with various cellular proteins, thereby mediating multi-
ple signal transduction pathways, including the phospha-
tidylinositol-3-OH-kinase (PI3K) and mitogen-activated
protein kinase pathways [8-10].
The survival of breast cancer cells, especially those
with HER2 gene amplification, is heavily dependent on
lipid metabolism [11]. HER2 overexpression increases
translation of fatty acid synthase (FASN) [12,13], and
FASN overexpression markedly increases EGFR and
HER2 signaling, which results in enhanced cell growth
[14]. Thus, FASN overexpression has been associated
with poor prognosis in breast cancer patients [15].
Kumar-Sinha et al. originally discovered a molecular
connection between FASN and HER2. These authors
showed that HER2 mediates FASN induction by activat-
ing the FASN promoter via a PI3K-dependent pathway
[16]. Menendez et al. s u g g e s t e dt h a tH E R 2o v e r e x p r e s -
sion could upregulate FASN gene transcription, protein
synthesis, protein stability and possibly phosphorylation
[17] and later showed that FASN inhibitors (for exam-
ple, cerulenin and C75) and small interfering RNAs
(siRNAs) targeting FASN specifically suppressed HER2
protein and mRNA expression by upregulating the
HER2-specific transcriptional repressor PEA3 [18]. Phar-
macologically induced or siRNA-induced inhibition of
FASN in breast cancer cells results in major changes in
the synthesis of phospholipids that, in turn, impair the
proper localization of HER2 to the cell membrane [19].
Recent findings have shown that FASN expression is
induced by HER2 overexpression, which activates the
PI3K/AKT pathway and subsequently stimulates the
mammalian target of rapamycin, leading to increased
FASN translation [12,16,20]. HER2 can also activate
sterol regulatory element binding protein-1c, resulting
in the upregulation of FASN transcription [19]. Agents
that target the HER2/PI3K/mammalian target of rapa-
mycin pathway have been shown to consequently down-
regulate FASN expression [12,21]; conversely, FASN
inhibitors block the protein expression and kinase activ-
ity of HER2 [18,22]. Blocking both FASN and HER2
results in the synergistic suppression of breast cancer
cell growth [18]. These studies suggest a potential role
for FASN in apoptosis, cell proliferation and invasion in
HER2-overexpressing breast cancer cells and indicate
the possibility that agents targeting FASN could be use-
ful for treating breast cancers, especially those in which
HER2 is overexpressed.
In this study, we further investigated the relationship
between HER2-regulated FASN tyrosine phosphoryla-
tion and FASN activity, as well as the role of FASN in
promoting cell invasion in HER2-overexpressing breast
cancer cells. Our data support a potential role for FASN
phosphorylation as a novel therapeutic target in HER2-
overexpressing breast cancer.
Materials and methods
Cell culture and reagents
SKBR3 and BT474 breast cancer were purchased from
American Type Culture Collection (Manassas, VA,
USA) and grown in cell culture medium (McCoy’s5 A
medium (Sigma-Aldrich, St. Louis, MO, USA) for
SKBR3 cells and RPMI-1640 medium (Sigma-Aldrich)
for BT474 cells) supplemented with 10% fetal bovine
serum, 62.5 μg/mL penicillin and 100 μg/mL streptomy-
cin (Sigma-Aldrich) for the specified times at 37°C in a
humidified atmosphere of 5% CO2. For the analysis of
HER2 signal transduction, cells were incubated in
serum-free medium overnight and then treated with the
HER2 inhibitor lapatinib (ChemieTek, Indianapolis, IN,
USA), the FASN inhibitor C75 (Sigma-Aldrich), epider-
mal growth factor (EGF; Sigma-Aldrich), insulin-like
growth factor 1 (IGF-1; Sigma-Aldrich) and/or human
recombinant HRG (Sigma-Aldrich) as indicated.
Mass spectrometry
To identify the proteins that are dephosphorylated as a
result of suppression of HER2, we immunoprecipitated
proteins with a monoclonal antibody detecting tyrosine
phosphorylation at residue 66 (PT66) and the lysates of
SKBR3 breast cancer cells that had been left untreated or
treated with lapatinib for 18 hours. The eluted proteins
were separated by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE), and the resulting gel
was cut into two identical halves. One half of the gel was
subjected to silver staining (Additional file 1A); the other
half was subjected to Western blot analysis (Additional
file 1B). Silver-stained bands from the untreated cells
(control) were excised. These bands corresponded to
bands in the Western blot that showed decreased expres-
sion in the cells treated with lapatinib versus untreated
control. The protein bands from the silver-stained gel
were subjected to analysis with an LTQ XL linear
ion-trap mass spectrometer (Thermo Scientific, West
Palm Beach, FL, USA) with an UltiMate 3000
high-performance liquid chromatography (Dionex, Ban-
nockburn, IL, USA) reverse-phase column (LC-Packings
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Mascot software (Matrix Science, Boston, MA, USA) was
used to search the mass spectra against the National
Center for Biotechnology Information database.
Kinase assay
For kinase assay, the FASN substrate was prepared by
immunoprecipitation. SKBR3 cells were incubated in
serum-free medium overnight, treated with 1 μM lapati-
nib for one hour to minimize the effect of HER2 kinase
and lysed with a lysis buffer. We used an anti-FASN
antibody (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) and protein G agarose beads (Millipore, Billerica,
MA) to immunoprecipitate FASN. Endogenous HER2
kinase was immunoprecipitated from the lysates of
SKBR3 cells treated with: 1) no agent (untreated con-
trol); 2) 50 ng/mL HRG for 15 minutes; 3) 1 μMl a p a t i -
nib for one hour, or 4) 1 μM lapatinib for one hour
followed by 50 ng/mL HRG for 15 minutes. To measure
kinase activity, we mixed the FASN substrate and HER2
kinase (endogenous HER2 or human recombinant HER2
(BPS Bioscience Inc., San Diego, CA, USA) as positive
control) in kinase reaction buffer (10 mM MnCl2,5μC
32P-g-a d e n o s i n e - 5 ’-triphosphate (ATP), 20 mM Tris-Cl
[pH, 7.5], 50 mM NaCl, 10 mM MgCl2,1m MN a F ,
1m MN a 3VO4,2 0m Mb-glycerophosphate, 1 mM
dithiothreitol and 20 μM ATP) for 30 minutes at 30°C.
Phosphorylated FASN was assessed by autoradiography
following SDS-PAGE.
Immunoprecipitation and Western blot analysis
SKBR3 cells were treated for one hour with: 1) med-
ium only (control); 2) 50 ng/mL HRG; 3) 1 μM lapati-
nib; or 4) 50 ng/mL HRG plus 1 μM lapatinib. BT474
cells were treated with: 1) medium only (control);
2) 50 ng/mL HRG for one hour; 3) 10 μM C75 for six
hours; or 4) 50 ng/mL HRG for one hour plus 10 μM
C75 pretreatment for five hours. Cells were lysed in
lysis buffer containing 1% Triton-X 100, 50 mM Tris-
Cl (pH, 8.0), 150 mM NaCl, 5 mM ethylenediaminete-
traacetic acid (pH, 8.0), 50 mM NaF, 1 mM Na3VO4,
50 mM b-glycerophosphate, a protease inhibitor cock-
tail (Roche, Indianapolis, IN, USA) and a phosphatase
inhibitor cocktail (Calbiochem-EMD Biosciences, San
Diego, CA, USA). FASN proteins were immunoprecipi-
tated via 2 μg anti-FASN antibody and a 50% protein
G agarose bead slurry, and the immunoprecipitated
samples were boiled and analyzed by Western blotting
as previously described [23]. Whole-cell lysates were
subjected to Western blotting as previously described
[24]. The following antibodies were used for Western
blot analysis: mouse monoclonal antibodies detecting
tyrosine phosphorylation (PT66) and b-actin (Sigma-
Aldrich); rabbit polyclonal antibodies detecting pHER2
(Tyr 1248), pHER3 (Tyr 1289), pAkt (S473), pErk1/2,
Akt, Erk1/2 and HER3 (Cell Signaling Technology,
Inc., Danvers, MA, USA); mouse monoclonal antibo-
dies detecting FASN, HER2 and HER3 (Santa Cruz)
and an Alexa Flour 680 goat anti-mouse immunoglo-
bulin (IgG) antibody, Alexa Flour 680 goat anti-rabbit
I g Ga n t i b o d ya n dA l e x aF l o u r6 8 0d o n k e ya n t i - g o a t
IgG antibody (Invitrogen Corporation, Carlsbad, CA,
USA). The membranes were washed extensively, and
the proteins were visualized and quantified using
Odyssey imaging software v1.2 (LI-COR Inc., Lincoln,
NE, USA). Representative results from three separate
experiments are reported.
Immunofluorescence analysis of subcellular protein
distribution
Modified immunofluorescence analysis was performed
as described previously [25]. Briefly, SKBR3 cells were
trypsinized and seeded onto a Nunc six-well Lab-Tek
chamber slide (Thermo Scientific) at a density of 1 ×
10
5 cells/well and cultured overnight. After 12 hours
of serum starvation, the culture medium was changed
to serum-free medium containing either untreated
control or 50 ng/mL HRG and the cells were treated
for an additional three hours. After treatment, cells
were fixed with 2% paraformaldehyde, permeabilized
with ice-cold methanol and blocked with 3% bovine
serum albumin solution in triethanolamine buffered
saline containing 0.1% Tween 20 (TBST). Chamber
slides were incubated with mouse anti-FASN and rab-
bit anti-HER2 primary antibodies (1:100 in phosphate-
buffered saline-Tween 20, Santa Cruz) overnight at
4°C. Slides were rinsed three times with TBST and
incubated with Alexa 488 (Ex 495/Em 519) donkey
anti-mouse and Alexa 594 (Ex 590/Em 617) donkey
anti-rabbit secondary antibodies (Invitrogen) for 30
minutes at room temperature. Finally, slides were
washed three times in TBST, rinsed with distilled
water and mounted with Faramount mounting medium
(Dako North America Inc., Carpinteria, CA, USA).
Slides were viewed and photographed using a Zeiss
LSM 710 immunofluorescence microscope.
siRNA transfection
Transient transfection of siRNAs was performed with
Oligofectamine reagent (Invitrogen) according to the
manufacturer’s instructions. Briefly, SKBR3 and BT474
cells were plated in six-well plates at a density of 3 ×
10
5 cells/well. Either 10 μLo f2 0μM FASN siRNA (si-
FASN, Thermo Scientific) or 10 μL of scrambled control
siRNA (Dharmacon Research Inc.) was transfected to
each well, and cells were incubated for 24 hours at 37°C
in a humidified CO2 incubator. Transfected cells were
used for Western blotting or cell invasion analyses.
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A modified FASN enzymatic activity assay was performed
as previously described [20]. Briefly, after overnight
serum starvation, SKBR3 and BT474 cells were incubated
for 12 hours in serum-free medium containing 1 μCi/mL
(2-
14C)acetate and no agent (control), 50 ng/mL HRG,
1 μM lapatinib, 10 μM C75, 50 ng/mL HRG plus 10 μM
C75 or 50 ng/mL HRG plus 1 μM lapatinib. Cells were
harvested in 1 × phosphate-buffered saline. The (2-
14C)
incorporated lipid was extracted with a solution of
chloroform and methanol (1:3) after treatment with
ddH2O and methanol (6:5). After being shaken for
30 minutes at room temperature, samples were centri-
fuged at 12,500 × g for five minutes, and the lower phase
was counted for fatty acid incorporation. Changes in
FASN activity were reported as a percentage compared
to untreated control cells. Each experiment was repeated
in triplicate.
Tumor cell invasion assay
To detect cell invasion, we used a QCM ndothelial cell
matrix cell invasion assay with a 24-well (8-μmp o r e s )
fluorometric matrigel invasion chamber (Millipore). To
investigate the role of lapatinib in cell invasion, we treated
SKBR3 and BT474 cells with 1) medium only (untreated
control); 2) 0.2 μM lapatinib; 3) 50 ng/mL HRG; or
4) 50 ng/mL HRG plus 0.2 μM lapatinib. To investigate
the role of C75 in cell invasion, we treated both SKBR3
and BT474 cells with: 1) medium only (untreated control);
2) 10 μM C75; 3) 50 ng/mL HRG; or 4) 50 ng/mL HRG
plus 10 μM C75. To evaluate the role of si-FASN in cell
invasion, we transfected both SKBR3 and BT474 cells with
scrambled siRNA or si-FASN for 24 hours. After 12 hours
of serum starvation, the transfected SKBR3 and BT474
cells were trypsinized and seeded at a density of 1 × 10
5
cells/well and then incubated in serum-free medium with
or without 50 ng/mL HRG. In the bottom well, 10% fetal
bovine serum medium was used as a chemoattractant.
Each experiment was performed in triplicate. After
36 hours of incubation, the cells remaining above the
insert membrane were removed by gentle scraping with a
sterile cotton swab. Cells that invaded through the matri-
gel to the bottom of the insert were fixed and stained with
crystal violet. Invading cells on representative sections of
each membrane were counted under light microscopy.
Under each treatment condition, the number of invading
cells was calculated as the percentage of invaded cells
compared with the control cultures. All experiments were
done at least thrice.
Zymography
SKBR3 and BT474 cells were incubated in serum-free
medium for an additional 12 hours after the cell invasion
assay and treated with no agent (control), 50 ng/mL
HRG, 1 μM lapatinib, 10 μM C75, 50 ng/mL HRG plus
10 μM C75 or 50 ng/mL HRG plus 1 μM lapatinib.
Matrix metallopeptidase 9 (MMP-9) has been associated
with invasion in HER2-overexpressing breast cancer
cells. To evaluate the effect of si-FASN on MMP-9 activ-
ity, we seeded SKBR3 and BT474 cells in 100-mm dishes
at a density of 1 × 10
6 cells/well; the next day, the cells
were transfected with either scrambled siRNA or si-
FASN for 24 hours. Then the transfected SKBR3 cells
were incubated in serum-free medium for an additional
12 hours and treated with: 1) no agent (control) or 2)
50 ng/mL HRG. After 24 hours of treatment, supernatant
medium was collected, concentrated (from 8 mL to
200 μL) by the use of an Amicon Ultra-15 centrifugal
filter (Millipore) and stored at -80°C for use in a zymo-
gram assay. Cells were harvested for Western blot analy-
sis. A modified zymogram assay was performed as
previously described [26]. The protease activity of MMP-
9 was assessed by SDS-PAGE with 8% zymogram gels
containing 0.2% (2 mg/mL) gelatin. Areas of protease
activity appeared as clear bands against a dark Coomassie
blue background where the protease had digested the
substrate.
Cell viability assay
SKBR3 and BT474 cells were trypsinized, counted and
seeded at a density of 8 × 10
3 cells/well on a 96-well
plate overnight. The next day, cells were treated with
0.2 μM lapatinib or 10 μM C75 with, or without,
50 ng/mL HRG for an additional 36 hours. Cell viability
was assessed with a CellTiter-Glo luminescent cell viabi-
lity assay kit (Promega, Madison, WI, USA) according to
the manufacturer’s instructions.
Statistical analysis
Data from FASN activity, cell viability and cell invasion
assays were analyzed using the Student’st w o - t a i l e d
t-test. P < 0.05 was considered statistically significant.
Results
FASN is phosphorylated by HER2 activation in HER2-
overexpressing breast cancer cells
As expected, lapatinib inhibited EGFR and HER2 phos-
phorylation in SKBR3 breast cancer cells. Lapatinib also
dephosphorylated other proteins, such as FASN, Hsp90
and Hsp70. Because of the known connection between
FASN and HER2 in breast cancer cells [12,16,18,27], we
focused on FASN for the subsequent experiments. We
further confirmed dephosphorylation of FASN by lapati-
nib by measuring total and phosphorylated FASN levels
in HER2-positive SKBR3 and BT474 breast cancer cells
with or without treatment with a clinically relevant
concentration of lapatinib [28] overnight (Additional
file 1C).
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ligand dependent, we incubated SKBR3 cells in serum-
free medium overnight and then treated the cells with
E G F ,H R Go rI G F - 1f o rt h ei n d i c a t e dt i m ec o u r s e .W e
found an increase in FASN phosphorylation upon treat-
ment with HRG (Figure 1A) but not with EGF or IGF-1
(data not shown). This finding suggests that HER3 or
HER4 is involved in FASN activation, presumably by
heterodimerization with HER2 [29]. HRG-induced
FASN phosphorylation and lapatinib-induced FASN
dephosphorylation were confirmed by the use of an
in vitro kinase assay with a FASN substrate (Figure 1B).
We evaluated the HRG-induced interaction between
FASN and HER2 in vivo with immunofluorescence
microscopy. Figure 2 demonstrates that FASN and
HER2 colocalized to the cell membrane upon HRG
treatment. Coimmunoprecipitation of FASN and HER2
showed that HRG induced interaction between FASN
and HER2 and tyrosine phosphorylation of FASN in
both SKBR3 and BT474 cells (Figure 3). Concomitant
with the lapatinib-induced FASN dephosphorylation the
HRG-induced interaction between FASN and HER2 was
also markedly suppressed by lapatinib (Figure 3A). The
changes in HER2 activity induced by HRG and lapatinib
were confirmed by the following findings: HRG induced
the tyrosine phosphorylation of HER2, HER3, Akt and
Erk1/2, which was inhibited by lapatinib, whereas
neither of these agents changed the total expression of
HER2, HER3, Akt, Erk1/2 and FASN in either SKBR3
(Figure 3C, left panel) or BT474 cells (Figure 3C, right
panel).
Tyrosine phosphorylation of FASN is critical for
maintaining FASN activity in breast cancer cells
The posttranslational modification of proteins, especially
phosphorylation, is closely associated with protein biolo-
gical activity [10]. We evaluated whether FASN activity
could be modulated by changes in FASN tyrosine phos-
phorylation levels in vivo. SKBR3 cells treated with HRG
(50 ng/mL) showed significantly increased FASN activity
(P < 0.001), and FASN activity was markedly inhibited
by lapatinib (P <0 . 0 0 1 )i nb o t hS K B R 3( F i g u r e4 A )a n d
BT474 cells (Figure 4B). This result shows that lapatinib
suppressed both basal FASN activity and HRG-induced
FASN activity (Figures 4A, B) and indicates that tyrosine
phosphorylation of FASN plays a critical role in main-
taining the physiological function of FASN in breast
cancer cells.
FASN inhibitor C75 suppresses FASN activity and FASN
tyrosine phosphorylation in breast cancer cells
Since HER2 phosphorylation and activity were sup-
pressed by FASN inhibitors in previous studies
[27,30,31], we further investigated whether tyrosine
phosphorylation of FASN could be inhibited by a
FASN inhibitor. We found that the FASN inhibitor
C75 suppressed both HRG-induced interaction
between FASN and HER2 and tyrosine phosphoryla-
tion of FASN in SKBR3 (Figure 5A) and BT474 cells
(Figure 5B). The changes in HER2 activity induced by
HRG and C75 were confirmed by the following find-
ings: HRG induced tyrosine phosphorylation of HER2,
HER3, Akt and Erk1/2, which was inhibited by C75,
whereas neither of these agents changed the total
expression of HER2, HER3, Akt, Erk1/2 and FASN in
both SKBR3 (Figure 5C, left panel) and BT474 cells
(Figure 5C, right panel).
We confirmed that HRG increased FASN activity (P <
0.001 in SKBR3 cells and P < 0.01 in BT474 cells) and
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Figure 1 FASN phosphorylation by HRG in SKBR3 cells.
(A) SKBR3 cells were incubated in serum-free medium overnight
and then treated with 50 ng/mL heregulin (HRG) for the indicated
times. FASN was immunoprecipitated and immunoblotted by the
use of a monoclonal phosphotyrosine (PT66) and anti-FASN
antibodies. (B) Immunoprecipitated FASN substrate was incubated
with HER2 kinase and radiolabeled with (g-P
32)-ATP for 30 minutes
at 30ºC, separated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis and visualized by autoradiography. Recombinant
HER2 kinase was used as a positive control. Western blotting for
FASN and HER2 was performed to confirm that equal amounts of
FASN or HER2 were used in each kinase assay.
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(Figure 6A) and BT474 cells (Figure 6B). These results
show that C75 suppressed both basal FASN activity (P <
0.01 in both cell lines) and HRG-induced FASN activity
(P < 0.001 in SKBR3 cells and P < 0.01 in BT474 cells).
These data indicate that C75-induced FASN depho-
sphorylation was involved in the suppression of FASN
physiological function in breast cancer cells.
Targeting FASN inhibits invasion of breast cancer cells
Previous studies have shown that inhibition of FASN
suppresses cell survival and proliferation in vitro and
in vivo [30-33]. Since invasion is one of the key steps
in the metastatic process, we further investigated the
role of FASN in the invasion of breast cancer cells. We
evaluated the effects of lapatinib, si-FASN and C75 on
the invasion of HER2-positive breast cancer cells.
Lapatinib at 0.2 μM or C75 at 10 μM, with or without
HRG, for 36 hours had no significant effect on cell via-
bility (Additional file 2). Without HRG, SKBR3 and
BT474 cells were minimally invasive (Additional file 3).
HRG-induced cell invasion was markedly inhibited by
0.2 μM lapatinib in both SKBR3 (Additional file 3A)
and BT474 cells (Figure 7A; P < 0.001 in both cell
lines). In both SKBR3 and BT474 cells, knockdown of
FASN by the transfection of si-FASN markedly inhib-
ited HRG-induced cell invasion (P < 0.001) compared
to invasion in scrambled siRNA-transfected cells trea-
ted with HRG (Additional file 3B and Figure 7B).
Knockdown of FASN by the transfection of si-FASN
was confirmed by Western blotting (Figure 7B). In
both SKBR3 and BT474 cells, 10 μM C75 also signifi-
cantly suppressed HRG-induced cell invasion (P <
0.001 in both cell lines) (Figure 8A and Additional files
3C, 4, 5). Since the activation and secretion of MMP-9,
a key enzyme in the degradation of extracellular
matrices that promotes tumor cell invasion, are signifi-
cantly induced by HRG in SKBR3 cells [34], we per-
formed a zymogram assay to investigate whether
MMP-9 is involved in the regulation of cell invasion.
We found that HRG increased the secretion and activ-
ity of MMP-9 in BT474 cells, whereas lapatinib
remarkably inhibited HRG-enhanced MMP-9 activity
by 80% in BT474 cells (Figure 8B). Transfection of si-
FASN significantly inhibited HRG-enhanced MMP-9
activity by 70% in BT474 cells (Figure 8B). C75 mark-
edly suppressed HRG-enhanced MMP-9 activity by
60% in BT474 cells (Figure 8B). These data indicate
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breast cancer cell invasion at least in part through
downregulation of MMP-9 activity.
Our findings support the following model: cell invasion
was regulated by the functional interaction between
FASN and HER2 in HER2-overexpressing SKBR3 and
BT474 breast cancer cells (Figure 9). HRG is known to
induce the interaction between HER3 and HER2, which
phosphorylates HER3 [7]. In our study, the activated
HER2 not only activated the PI3K/Akt and mitogen-
activated protein kinase signaling pathways but also
enhanced FASN activity by direct interaction and phos-
phorylation, leading to an increase in cell invasion.
When FASN activity was suppressed by either C75 and
si-FASN or lapatinib through the downregulation of
HER2-induced FASN phosphorylation, cell invasion was
significantly inhibited in HER2-overexpressing SKBR3
and BT474 breast cancer cells. The model proposed in
Figure 9 is supported by our findings and those of
others.
Discussion
Our results support the hypothesis that HER2-mediated
FASN phosphorylation plays an important role in breast
cancer progression and may be a novel therapeutic tar-
get in HER2-overexpressing breast cancer cells. Lapati-
nib inhibits EGFR and HER2 phosphorylation in breast
cancer cells [35], and it is an effective treatment for
patients with HER2-positive metastatic breast cancer
that has progressed after prior therapies [3]. We pre-
viously showed that lapatinib induces apoptosis in tras-
tuzumab-resistant breast cancer cells [36]. Our current
results suggest that FASN dephosphorylation plays an
important role in the antitumor activity of lapatinib in
HER2-positive breast cancer cells. Recently, lapatinib
was shown to suppress HER2 phosphorylation and ubi-
quitination, resulting in a significant accumulation of
inactive HER2 receptors at the cell surface, which
enhanced the effect of trastuzumab-induced, antibody-
dependent cellular cytotoxicity in HER2-overexpressing
breast cancer cells [37]. Vazquez-Martin et al. [38]
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Page 7 of 15demonstrated that lapatinib enhanced HER2 extracelluar
domain shedding and inhibited HER2 phosphorylation
and activity, thereby suppressing HER2-overexpressing
cancer cell growth. Our results show that lapatinib inhi-
bits HER2-induced FASN phosphorylation and sup-
presses FASN activity in HER2-overexpressing breast
cancer cells. Treatment with C75 or lapatinib inhibits
the survival of HER2-positive breast cancer cells
[30-33,36].
In many types of cancer, including breast cancer,
FASN overexpression robustly induces de novo lipogen-
esis. The generated lipids are integrated into membrane
lipid rafts and modulate membrane receptor tyrosine
kinases (for example, the EGFR family) which, in turn,
results in the initiation of oncogenic signaling pathways
involving cell survival, proliferation, migration and inva-
sion [19,39]. FASN overexpression increases EGFR and
HER2 protein expression and tyrosine phosphorylation,
and thereby amplifies oncogenic signaling pathways that
contribute to tumorigenic transformation [14].
C75 is a competitive, irreversible inhibitor of FASN
[15]. Experimental evidence has demonstrated that C75
can induce apoptosis in breast cancer cell lines and
delay tumor growth in human breast cancer xenografts.
The antitumor activity of C75 is not well defined at
the molecular level, and it may vary depending on
the model systems used. In their original study, Menen-
dez et al. [18] described the mechanism of HER2
downregulation by C75. Briefly, C75 suppressed HER2
protein and mRNA expression by upregulating the
HER2-specific transcriptional repressor PEA3. C75 treat-
ment resulted in decreased phospholipid synthesis which
impaired the proper localization of HER2 to the cell
membrane in breast cancer cells [19]. The suppression
of HER2 kinase activity by C75 results in the synergistic
promotion of apoptosis induced by other HER2-directed
therapies in breast cancer cells [14,22,27].
Whether FASN is regulated post-transcriptionally in
cancer cells remains unclear. Several studies have
reported associations between the AMP-activated pro-
tein kinase (AMPK) and fatty acid metabolism. In one
study, nicotine activated AMPK in 3T3L1 adipocytes,
resulting in enhanced threonine phosphorylation and
consequent inhibition of FASN [40]. It is possible that
different FASN phosphorylation statuses could modulate
FASN activity differently; that is, threonine phosphoryla-
tion may inhibit FASN activity, whereas, tyrosine phos-
phorylation may increase FASN activity. Furthermore,
AMPK activation could be the key factor in the cardiac-
protective action of lapatinib in contrast to the cardiac
toxicity of trastuzumab, which was suggested in two
independent studies that demonstrated the ability of
reversible dual EGFR/HER2 inhibitors (lapatinib and a
lapatinib-like agent, GW2974) to activate AMPK in
HER2-expressing human cardiomyocytes [41,42]. How-
ever, we did not observe lapatinib-induced AMPK
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Page 9 of 15activation in our experiment setting, probably because of
the differences in dose (25 or 50 μM GW2974 and lapa-
tinib in the previous studies versus 0.2 or 1.0 μM lapati-
nib in our experiment) or because of tissue-specific
response (cardiomyocyte versus breast cancer cell).
Moreover, C75 was also reported by Landree et al. to
modulate AMPK phosphorylation and activity in neu-
rons [43]. However, under our treatment conditions,
AMPK activation was not altered, a finding that was
confirmed by the absence of changes in AMPK substrate
acetyl-CoA carboxylase phosphorylation (data not
shown). Therefore, the AMPK-induced threonine phos-
phorylation of FASN likely did not play a role in the
regulation of FASN activity by the relatively low dose of
lapatinib or C75 we used in HER2-positive breast cancer
cells.
Our data demonstrate that HRG can activate the
HER2 tyrosine kinase (not the serine or threonine
kinase), thus leading to interaction between HER2 and
FASN and subsequently inducing the tyrosine phosphor-
ylation of FASN in human breast cancer cells. Lapatinib
and C75 abrogated the colocalization of FASN and
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Figure 7 HRG-induced invasion in HER2-positive BT474 breast cancer cells treated with lapatinib or siRNA targeting FASN. (A) BT474
cells were treated with 50 ng/mL HRG or 50 ng/mL HRG plus 0.2 μM lapatinib for 36 hours. The invaded BT474 cells were stained with crystal
violet and counted under a microscope. Representative microscopic images are shown. The changes in cell invasion compared with HRG-
induced cell invasion are shown in a bar graph. All experiments were done three times. A simple t-test was used to assess differences in the
number of invaded cells between any two experimental conditions. *, statistically significant compared with cells treated with HRG; P < 0.05 was
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Page 10 of 15HER2 and suppressed the tyrosine phosphorylation of
FASN in both SKBR3 and BT474 cells. We showed a
direct correlation between the tyrosine phosphorylation
and activity of FASN in breast cancer cells. HRG
enhanced FASN activity (that is, lipid synthesis),
whereas lapatinib and C75 suppressed it. Since these
treatments (HRG, lapatinib and C75 changed the levels
of FASN protein expression in either SKBR3 or BT474
cells, the effects of these agents on FASN activity are
likely directly related to changes in FASN tyrosine phos-
phorylation levels. Although C75 directly binds to FASN
and inhibits its activity [13], in our study, C75 also sup-
pressed HRG-induced FASN tyrosine phosphorylation, a
mechanism that might be partly involved in further
decreasing FASN activity. This novel finding indicates
that the regulation of FASN activity by tyrosine
phosphorylation may play an important role in the cell
growth, invasion and metastasis of HER2-overexpressing
breast cancer.
We showed that suppression of FASN by C75 or si-
FASN inhibited the HRG-enhanced invasion of HER2-
overexpressing breast cancer cells. HRG has been shown
to induce the interaction of HER2 with HER3 and
HER4, resulting in increased tyrosine phosphorylation of
HER2 in breast cancer cells and, thus, increased metas-
tasis by enhancing tumor cell invasion and intravasation
in vivo [44]. The role of HER3 and HER4 in the regula-
tion of FASN is unknown. However, our observation
that FASN phosphorylation was induced by HRG sug-
gests that HER3 is involved in FASN activation, presum-
ably by heterodimerization with HER2 [45,46]. HER4
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Figure 8 Cell invasion and activity of MMP9 in HER2-positive BT474 breast cancer cells with suppressed FASN. (A) BT474 cells were
treated with 50 ng/mL HRG or 50 ng/mL HRG plus 10 μM C75 for 36 hours. Cells shown in the microscopic image represent invasive cells. The
changes in cell invasion compared with HRG-induced cell invasion are shown as a percentage in the bar graph. All experiments were done
three times. A simple t-test was used to assess differences in the number of invaded cells between any two experimental conditions. *,
statistically significant compared with cells treated with HRG; P < 0.05 was considered statistically significant. (B) BT474 cells were treated as
described in Figures 7A, B and 8A, and the medium was harvested for zymogram assay as described in Materials and methods. MMP-9 activity is
shown as the digested clear band in Coomassie blue-stained gel containing 0.2% gelatin.
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Page 11 of 15phosphorylation, because HER4 was not detectable in
BT474 and SKBR3 cells. HRG-induced activation of the
HER2 signaling pathway plays an important role in the
activation of MMP-9. Targeting endogenous HRG by
anti-sense cDNA significantly reduces HER2 activity,
inhibits MMP-9 activity and subsequently suppresses
cell invasion [47]. Yao et al. [48] demonstrated that
HRG increases MMP-9 activity, which is completely
inhibited by the PKC inhibitor RO318220 and p38
kinase inhibitor SB293580 and partially suppressed by
the MEK-1 inhibitor PD098059 but not blocked by the
PI3K inhibitor wortmannin. In contrast, these authors
found that the PI3K inhibitor LY294002 markedly
blocks EGF-enhanced MMP-9 activity. In our study, we
showed that inhibition of the HER2 signaling pathway
by lapatinib significantly suppressed FASN activity and
Figure 9 Regulation of cell invasion through functional interaction between FASN and HER2 in HER2-overexpressing breast cancer
cells. When HRG binds to HER3, HER2 interacts with HER3 and induces tyrosine phosphorylation of HER3. The activated HER2 not only
stimulates the PI3K/Akt and MAPK signaling pathways but also induces tyrosine phosphorylation of FASN and upregulation of FASN activity,
leading to increased cell invasion. Suppression of FASN indirectly (for example, with lapatinib) or directly (for example, with C75 or si-FASN)
inhibits invasion of HER2-overexpressing breast cancer cells.
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ity, resulting in the inhibition of cell invasion.
Conclusions
In summary, our data demonstrate that the inhibition of
HER2 kinase activity by lapatinib results in decreased
FASN tyrosine phosphorylation and reduced FASN enzy-
matic activity, which further downregulates HER2 signal-
ing and results in suppressed breast cancer cell invasion.
Future studies will focus on identification of the FASN
tyrosine phosphorylation sites induced by HER2 and the
role of HER3 in the regulation of FASN phosphorylation.
Additional material
Additional file 1: Protein tyrosine phosphorylation in HER2-positive
breast cancer cells treated with lapatinib. (A and B) SKBR3 breast
cancer cells were treated with 1 μM lapatinib or DMSO (control)
overnight (18 hours). Equal amounts of protein from total whole-cell
lysates were immunoprecipitated with the antiphosphotyrosine antibody
PT66 and separated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis. Steady-state protein levels of phosphotyrosine were
assessed by silver staining (A) and Western blotting (B). (C)
Phosphotyrosine immunoprecipitated complexes were obtained from
SKBR3 and BT474 cells and detected by Western blotting on FASN.
Additional file 2: Viability of cells treated with low doses of
lapabinib or C75. SKBR3 and BT474 cells were seeded at a density of 8
×1 0
3 cells/well on a 96-well plate. The next day, cells were treated with
0.2 μM lapatinib or 10 μM C75 with or without 50 ng/mL HRG for an
additional 36 hours. Cell viability assay was performed by the use of the
CellTiter-Glo luminescent cell viability assay kit (Promega Corporation)
according to the manufacturer’s instructions.
Additional file 3: Implication of FASN and HER2 in the invasion of
HER2-positive SKBR3 breast cancer cells. We assessed cell invasion
using a matrigel invasion chamber as described in Materials and
methods. (A) SKBR3 cells were treated with 50 ng/mL HRG or 50 ng/mL
HRG plus 0.2 μM lapatinib for 36 hours. The changes in cell invasion
compared with HRG-induced cell invasion were shown as a percentage
in a bar graph. All experiments were done three times. A simple t-test
was used to assess differences in the number of invaded cells between
any two experimental conditions. *, statistically significant compared with
cells treated with HRG; P < 0.05 was considered statistically significant.
(B) SKBR3 cells transfected with either scrambled siRNA or si-FASN were
treated with 50 ng/mL HRG for 36 hours. The efficiency of si-FASN
knockdown was confirmed by Western blotting for FASN and b-actin.
The changes in cell invasion compared with the invaded scrambled
siRNA-transfected untreated cells were shown as a percentage in a bar
graph. All experiments were done three times. A simple t-test was used
to assess differences in the number of invaded cells between any two
experimental conditions. *, statistically significant compared with
scrambled si-RNA-transfected cells treated with HRG; P < 0.05 was
considered statistically significant. (C) SKBR3 cells were treated with 50
ng/mL HRG or 50 ng/mL HRG plus 10 μM C75 for 36 hours. The changes
in cell invasion compared with the invaded HRG-induced cell invasion
were shown as a percentage in a bar graph. All experiments were done
three times. A simple t-test was used to assess differences in the number
of invaded cells between any two experimental conditions. *, statistically
significant compared with cells treated with HRG; P < 0.05 was
considered statistically significant.
Additional file 4: Cell invasion in SKBR3 cells treated with C75 or
lapatinib. Cells were trypsinized and seeded at a density of 1 × 10
5 per
insert. To investigate the role of lapatinib in cell invasion, we treated
SKBR3 cells with untreated control or 0.2 μM lapatinib. To investigate the
role of C75 in cell invasion, we treated both SKBR3 and BT474 cells with
an untreated control or 10 μM C75. To evaluate the role of si-FASN in
cell invasion, we transfected cells with scrambled siRNA or si-FASN for 24
hours. After 12 hours of serum starvation, the transfected cells were
trypsinized and seeded at a density of 1 × 10
5 per insert and then
incubated in serum-free medium. In the bottom well, 10% fetal bovine
serum medium was used as a chemoattractant. After 36 hours of
incubation, the invaded cells were stained with crystal violet and
counted under a microscope. Representative microscopic images are
shown. Invasion in treated cells is shown in a bar graph as a percentage
of untreated (control) cells. All experiments were done three times.
Additional file 5: Cell invasion in BT474 cells treated with C75 or
lapatinib. Cells were trypsinized and seeded at a density of 1 × 10
5 per
insert. To investigate the role of lapatinib in cell invasion, we treated cells
with untreated control or 0.2 μM lapatinib. To investigate the role of C75
in cell invasion, we treated both SKBR3 and BT474 cells with an
untreated control or 10 μM C75. To evaluate the role of si-FASN in cell
invasion, we transfected cells with scrambled siRNA or si-FASN for 24
hours. After 12 hours of serum starvation, the transfected cells were
trypsinized and seeded at a density of 1 × 10
5 per insert and then
incubated in serum-free medium. In the bottom well, 10% fetal bovine
serum medium was used as a chemoattractant. After 36 hours of
incubation, the invaded cells were stained with crystal violet and
counted under a microscope. Representative microscopic images are
shown. Invasion in treated cells is shown in a bar graph as a percentage
of untreated (control) cells. All experiments were done three times.
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AMPK: AMP-activated protein kinase; EGFR: epidermal growth factor
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